Melanotan-2

What is Melanotan-2?#

Melanotan-2 is a peptide that has been studied in preclinical and clinical research models for its potential therapeutic properties.

Mechanism of Action#

Mechanistic overview. Melanotan-2 (MT‑II; Ac‑Nle‑Asp‑His‑D‑Phe‑Arg‑Trp‑Lys‑NH2) is a cyclic α‑MSH analogue that acts as a nonselective melanocortin receptor agonist, primarily engaging class A GPCRs MC1R–MC5R to elevate cAMP via Gs and trigger downstream kinase and transcriptional programs in a tissue‑specific manner (pigmentary, metabolic, and behavioral). In addition, systemic MT‑II can activate mast cells to release histamine, producing H1 receptor–mediated hypothermia independent of canonical melanocortin receptors (off‑target).

Receptor binding profile and selectivity. In radioligand competition assays (vs [125I]NDP‑MSH) MT‑II binds human melanocortin receptors with the following approximate Ki values: MC1R ≈ 0.67 nM, MC4R ≈ 6.6 nM, MC3R ≈ 34 nM, and MC5R ≈ 46 nM, indicating highest affinity at MC1R and MC4R with lower affinity at MC3R/MC5R; MC2R is not activated by MSH analogues. Functionally, MT‑II reduces food intake in wild‑type mice, and this anorexigenic effect is abolished in MC4R‑deficient mice, implicating MC4R as the principal mediator of the appetite‑suppressing action.

Canonical signaling pathways. Across MCR subtypes, the dominant coupling is Gs → adenylyl cyclase → cAMP → PKA with downstream phosphorylation of CREB and transcriptional effects; additional subtype‑specific modalities have been reported, including phosphoinositide/PLC signaling for MC3R and context‑dependent JAK/STAT linkages for MC5R. At MC4R, agonists differ in temporal cAMP signaling and desensitization; MT‑II belongs to a subset that can induce prolonged cAMP signaling after agonist withdrawal, a ligand‑dependent kinetic property that may contribute to persistent physiological effects.

Melanocyte targets and pigmentation (MC1R). In melanocytes, MT‑II activation of MC1R elevates cAMP and PKA activity, increases the micropthalmia‑associated transcription factor (MITF), and upregulates melanogenic enzymes, notably tyrosinase, leading to increased eumelanin synthesis and tanning/photoprotection. MT‑II is an MC1R agonist in melanocytes, though somewhat weaker than afamelanotide for MC1R‑driven cAMP, consistent with its broader receptor profile.

CNS mechanisms: appetite and arousal (MC3R/MC4R). In the hypothalamus, melanocortin signaling from POMC neurons decreases food intake via MC4R‑expressing neurons; MT‑II’s anorexigenic effect requires MC4R, aligning with central melanocortin control of energy balance. Ligand‑dependent persistence of MC4R cAMP signaling may influence in vivo durability of responses. MT‑II and related analogues also elicit prosexual behaviors in rodents and are clinically translated as bremelanotide (PT‑141), consistent with central melanocortin mechanisms involving MC4R/MC3R in arousal circuits.

Peripheral mechanisms: MC5R and exocrine/metabolic actions. MC5R is broadly expressed in exocrine glands (sebaceous, lacrimal, preputial) and in skeletal muscle and adipose tissue. Genetic studies show MC5R is required for normal exocrine secretion and hair/skin lipid content; agonism can modulate lipid mobilization in adipocytes and glucose uptake/thermogenesis in muscle. MT‑II can activate MC5R but is less potent than selective MC5R agonists; thus, some peripheral metabolic or secretory effects of MT‑II may be mediated through MC5R where expressed.

Off‑target mechanism: mast cell activation and histamine H1 signaling. Systemic (e.g., intraperitoneal) MT‑II in mice provokes transient hypometabolism/hypothermia that persists in mice lacking MC1R, MC3R, MC4R, or MC5R, demonstrating a non‑melanocortin receptor mechanism. The hypothermia is abolished in mast cell–deficient KitW‑sh/W‑sh mice, MT‑II elevates plasma histamine, and pharmacological or genetic blockade of histamine H1 receptors markedly attenuates the response, establishing a mast cell → histamine → H1R pathway. MT‑II activates mast cells via MRGPRB2‑dependent and independent mechanisms; route of administration modulates this confounder, with subcutaneous dosing reducing histamine‑mediated hypothermia while preserving central MC4R‑dependent hypermetabolism.

Integrated mechanism of action. MT‑II is a nonselective melanocortin agonist with highest functional relevance at MC1R (pigmentation via cAMP/PKA→MITF→tyrosinase) and MC4R (central appetite suppression and energy balance with ligand‑dependent cAMP kinetics), and contributory actions at MC3R and MC5R depending on tissue expression and signaling context. Systemically, MT‑II can additionally activate mast cells to release histamine and trigger H1R‑mediated hypothermia, an off‑target mechanism independent of MC1R/3R/4R/5R that is important for interpreting in vivo pharmacology.

Therapeutic Applications#

Key evidence summary

Preclinical applications and outcomes

• Erectile function mechanisms: In rats, intracerebral, intrathecal, and intravenous MT‑II produced dose‑dependent increases in spontaneous erections, with associated yawning/grooming after central dosing, implicating central melanocortin pathways. Pharmacologic dissection showed spinally administered SHU‑9119 blocked spinal MT‑II–induced erections, whereas intrathecal blockade did not prevent forebrain‑induced effects, indicating distinct central sites of action. In anesthetized rabbits, MT‑II increased intracavernosal pressure (ICP), an effect abolished by bilateral pudendal nerve ablation and by the NOS inhibitor L‑NAME, supporting neuronal and NO dependence. Isolated rabbit corpus cavernosal strips showed no direct relaxation to MT‑II, indicating minimal peripheral smooth muscle effect.

Clinical applications and outcomes

• Erectile dysfunction (psychogenic): Double‑blind, placebo‑controlled crossover study in 10 men with psychogenic ED using subcutaneous MT‑II (0.025–0.157 mg/kg) with RigiScan monitoring over 6 hours. Results: 8/10 achieved >80% rigidity; mean duration ~38 minutes vs ~3 minutes on placebo; onset 15–270 minutes. Adverse events were dose‑dependent, most commonly nausea, stretching, yawning, and decreased appetite; generally mild at 0.025 mg/kg.
• Erectile dysfunction (organic): In a similar controlled study of men with organic ED, erections occurred after 63% of MT‑II injections vs 5% with placebo; mean responder rigidity score 6.9/10; tip rigidity >80% lasted ~45 minutes vs ~2 minutes with placebo. Subjective sexual desire increased versus placebo. Adverse events mirrored those above, led by nausea and autonomic symptoms.
• Tanning/photoprotection origin: In a Phase I tanning study, MT‑II increased skin pigmentation and unexpectedly elicited pro‑erectile responses, which catalyzed subsequent ED trials; commonly reported side effects included nausea and penile erections.

Safety signals and dermatologic outcomes

• Case reports document temporal associations between MT‑II exposure and eruptive melanocytic nevi, atypical nevi, and melanoma in situ, including a melanoma in situ diagnosed four weeks after starting MT‑II obtained from a compounding pharmacy. These observations raise concern but do not establish causality; clinicians are advised to maintain vigilance.

Conclusions Preclinical data support MT‑II’s central MC4‑mediated, NO‑dependent erectogenic mechanism. Early clinical crossover trials show significant short‑term efficacy in psychogenic and organic ED as measured by RigiScan rigidity thresholds and duration, with predictable, mostly transient adverse effects led by nausea. MT‑II’s tanning origins and the emergence of dermatologic safety signals, including reports of melanoma in situ, underscore the need for regulated use and further controlled safety studies.

Preclinical Evidence#

Overview Melanotan-2 (MT-II) is a nonselective melanocortin receptor agonist with high activity at MC4R and MC1R. Preclinical work established a central, nitric oxide–dependent erectogenic mechanism without direct cavernosal smooth muscle relaxation. Early human studies explored MT‑II primarily for erectile dysfunction (ED), with the pro‑erectile effect first noted in a Phase I tanning study. Clinical case reports also describe dermatologic safety signals, including eruptive nevi and melanoma in situ temporally associated with MT‑II exposure.

Research Evidence Quality#

Overview Melanotan‑2 (MT‑II) is a cyclic α‑MSH analog developed in the 1990s. The formal human evidence base is small and early‑phase. Efficacy signals exist for erectile function and sexual desire in short, crossover trials; tanning was observed in a pilot Phase I setting. Safety concerns are prominent: high rates of nausea in trials and multiple case reports of serious harms (e.g., priapism, renal infarction), alongside major quality and regulatory issues with illicit products. Long‑term safety, including carcinogenic risk, has not been established. Overall, the evidence base is limited in size, duration, and scope.

Extent and quality of clinical evidence • Erectile dysfunction: Two small double‑blind, placebo‑controlled crossover studies in men with psychogenic or organic ED showed that subcutaneous MT‑II produced penile erections without erotic stimulation and increased sexual desire. In a 20‑man trial, erections occurred after 27/39 (69%) MT‑II injections vs 1/41 placebo, with mean tip rigidity >80% for ~41 minutes; sexual desire increased after 68% of MT‑II doses (P<0.01) (nausea 38%, severe ~15%). Methods included 6‑hour RigiScan monitoring; no serious AEs were reported in‑trial. A smaller psychogenic ED pilot (≈10 men) reported 8/10 achieving >80% rigidity with mean ~38 min vs ~3 min on placebo. • Tanning/photoprotection: Early Phase I work observed increased pigmentation after subcutaneous dosing; reviews report that cumulative exposure ~0.1 mg/kg was associated with tanning, and tanning effects were first noted during development efforts, which later pivoted due to erectogenic effects. Controlled human data demonstrating clinically meaningful photoprotection are not available in the retrieved texts. • Development status: Registry searching did not identify any advanced‑phase programs. Published human work is confined to small, short DBPC crossover trials and early Phase I pilots; there is no evidence of Phase 2/3 confirmation.

Adverse events and harms • In controlled trials: Nausea was frequent (≈38% of injections), with severe nausea in ≈15%; yawning/stretching were common; vomiting was rare; no serious adverse events were recorded during the monitored study periods. • Serious harms in case literature:

• Priapism following self‑injection of melanotan required clinical management.
• Renal infarction (≈50% of a kidney) occurred in a user who had injected ~27 mg over 6 months; forensic testing confirmed MT‑II in the sample. Prior reports include rhabdomyolysis and renal failure.
• A melanoma was diagnosed in a young woman after a 3–4‑week course of 1 mg every other day combined with sunbed use; causality is unproven but biologically plausible, and α‑MSH analogs may influence melanocytic biology. • Population‑level synthesis: A systematic review of injecting image/performance‑enhancing drug use notes MT‑II harms are documented largely as single cases or small series, including priapism, pigmentary changes/naevi, systemic toxicity, and GI/neurologic symptoms.

Product quality and regulatory concerns • Illicit‑market products show variable content (4.32–8.84 mg measured vs 10 mg labeled), impurities (4.1–5.9% in some samples), poor labeling/traceability, and potential sterility breaches. Authorities have classified such products as unauthorized medicines and acted against vendors; injection practices pose additional infectious risks. • MT‑II is unlicensed for tanning or ED; regulators and dermatologists warn of unproven benefits and potential harms, especially with combined UV exposure.

Key limitations and evidence gaps • Small, short studies using surrogate endpoints: ED trials rely on RigiScan monitoring over 6 hours with small samples; external validity and long‑term benefit are unknown. • Tolerability constraints: High nausea rates and other central effects limit practicality; optimal dose‑response and PK are insufficiently characterized. • Lack of long‑term safety: No prospective data on melanoma incidence, cardiovascular/renal outcomes, or other chronic risks; case reports cannot establish incidence or causality. • Photoprotection claims unsubstantiated: While pigmentation can increase, controlled clinical evidence for reduced UV damage or skin‑cancer risk was not identified. • Product and access issues: Most real‑world use involves unregulated, variably composed injectable products; this undermines reproducibility and safety assessment.

Criticisms • Ethical and regulatory: Use for cosmetic tanning lacks medical indication; products are unauthorized and often sourced illicitly, with contamination/sterility risks. • Safety signals vs. uncertain benefit: Reports of serious harms (priapism, rhabdomyolysis/renal injury; possible melanoma association) contrast with limited, short‑term efficacy evidence; professional bodies caution against use.

The evidence base for Melanotan‑2 is limited to small, short human trials showing erectogenic activity and increased sexual desire, and early observations of tanning. There are no robust data on long‑term efficacy or safety, including photoprotection or cancer outcomes. Adverse effects are common in trials (notably nausea), and serious harms are reported in case literature. The unlicensed, illicit supply chain introduces significant quality and infectious risks. On balance, current evidence quality is low, the extent is narrow, and key gaps include long‑term safety and standardized, regulated formulations.

Evidence Gaps and Limitations#

The current evidence base for Melanotan-2 consists primarily of preclinical studies. Key limitations include:

• No completed randomized controlled trials in humans
• Most data derived from animal models, limiting direct translatability
• Publication bias may favor positive results
• Long-term safety data in humans is not available
• Optimal dosing for human applications has not been established

Key Research Findings#

Melanocortin receptor agonists, penile erection, and sexual motivation - human studies with Melanotan II, published in International Journal of Impotence Research (Wessells H et al., 2000; PMID: 11035391):

• The study showed increased sexual desire of 68% of MT II doses vs 19% of placebo

Related Reading#

• Melanotan-2 research studies and evidence
• Melanotan-2 dosing protocols
• Melanotan-2 side effects profile
• Afamelanotide research guide
• LIB-01 research guide